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The success of whole organ transplan-
tation has been one of the least pre-
dicted events in the history of 
medicine. In 1961 , the Nobel Laureate 
Burnet wrote in the New England 
Journal of Medicine that "much 
thought has been given to ways by 
which tissues or organs not genetically 
and antigenically identical with the pa-
tient might be made to survive and 
function in the alien environment. On 
the whole , the present outlook is 
highly unfavorable to success . .. "1 . 
This pessimistic view was published 
only a year before the avalanche of 
successful clinical renal transplanta-
tions in 1962 and 1963 that extended 
such procedures beyond the occa-
sional identical and fraternal twin 
cases of the mid and late 1950s. 
Within and outside of the medical 
establishment , the frenzied pace of de-
velopments in 1962 and 1963 dismayed 
and dumbfounded critics, many of 
whom were unaware of what had been 
accomplished already. In the spring of 
1964, an editorial beginning with the 
word 'Cannibalizing' was published in 
the Annals of Internal Medicine ques-
tioning again the inherent feasibility of 
these efforts as well as the ethical 
basis2. Responses in an ensuing issue 
including a letter by me reflected a 
spectrum of views held by basic and 
clinical investigators3. By the summer 
of that year, I published a detailed ac-
count of our experience4 in which the 
majority of kidney recipients had 
achieved long survival with social and 
vocational rehabilitation. However, 
these dev elopments were already late 
in a long, but at first slowly unfolding, 
story. 
The earliest beginnings 
Heterotransplantation . - The first 
clinical efforts at renal transplantation 
predated the water-shed years of 1962 
and 1963 by half a century . The first 
known attempts at clinical renal trans-
plantation by vascular anastomoses 
were made without immunosuppres-
sion between 1906 and 1923 with pig, 
sheep, goat , and subhuman primate 
donors. Jaboulay of Lyon5 and the 
German U nger6 made the first of these 
foredoomed efforts , but others fol-
lowed as summarized elsewhere4, 7. 
None of the kidneys functioned for 
long if at all and the human recipients 
died from a few hours to nine days 
later. 
Although the trials were carried out 
with little or no understanding that 
there was a biologic barrier to success , 
some principles were clearly de-
lineated . The applicability of vascular 
suture techniques , and even the possi-
bility of using pelvic implantation sites 
were either envisioned or actually 
practiced. No further clinical renal 
heterotransplantations (animal to 
man) were tried again until 1963 when 
systematic and surprisingly successful 
clinical trials were made with chim-
panzee8 and baboon9 kidneys . Little 
noted at the time or subsequently were 
attempts at chimpanzee to human 
heart transplantation by Hardy with 
intraoperative death 10 and transplan-
tation of 3 chimpanzee liver hetero-
graftsll , 12, 13 of which 2 behaved indis-
tinguishably from homograftsll, 13. 
The eventual death of all of the reci-
pients of animal organs ended hetero-
transplantation trials for 15 years until 
Bailey's baboon to human heart trans-
plantation 14. 
Homotransplantation. - The first 
human to human kidney transplanta-
tion (homotransplantation) was re-
ported in 1936 by the Russian Yo-
ronoyl5 who transplanted a kidney 
from cadaver donor of B+ blood type 
to a recipient of 0+ blood type in viola-
tion of what have become accepted 
rules of tissue transfer4. The fact that 
the donor had been dead for 6 hours 
further precluded hope of success . The 
recipient died 48 hours later without 
making urine. Although the possibility 
that there would be an immune barrier 
to success was not obvious to most 
early clinicians , 'Yoronoy perceived 
this problem , although imprecisely. A 
more complete understanding awaited 
the classical studies of Medawar with 
rodent skin grafts which established 
the immunologic basis of rejection l6. 
In the 20 years following Yoronoy's 
case , sporadic further efforts at renal 
homotransplantation were made with-
out effective immunosuppression as 
documented by Groth7. The hete-
rotopic extraperitoneal technique of 
renal transplantation which became 
today's standard was developed by the 
French surgeons Dubost17, KuSS I8, 
and Servelle19 and their associates. 
John Merrill, the Boston nephrologist , 
had seen the extraperitoneal opera-
tion while travelling in France in the 
early 1950s as was mentioned by 
Hume et a]2o . This technique was 
adapted for the historically important 
identical and fraternal twin cases in 
Boston21, 22 . Variations of the opera-
tion shown in Figure 1 are used today 
worldwide. 
As isolated results , none of the 
foregoing efforts, or even all put to-
gether, would have had major signifi-
cance . The principal ingredients of 
organ transplantation , namely im-
munosuppression , tissue matching, 
and organ procurement (and preserva-
tion) were either unknown or so unde-
veloped that grafting of the kidney at a 
practical level was only a dream. Ex-
tension of transplantation beyond the 
kidney was beyond imagination. No 
trace can be found in the literature of 
transplantation of extrarenal organs 
until the mid 1950s when Welch de-
scribed auxiliary (heterotopic) liver 
transplantation23, and when Willman 
and Hanlon24, and Shumway25 showed 
the technical feasibility of heart trans-
plantation. Transplantation of the 
pancreas which had been used as a 
physiologic preparation by Houssay26 
was revived in the experimental 
laboratory in 1960 by Lillehei et aF7. 
Thus, the astonishing developments 
in transplantation of all these organs 
became a story of the last quarter cen-
tury . I will provide here some reminis-
cences of this era and speculate about 
how the momentum of this progress 
can be sustained and accelerated. Such 
hopes derive in part from the seminal 
contributions already made by the 
pharmaceutical industry and from the 
revolutionary changes in drug de-
velopment that have expedited the 
search for better drugs to combat re-
jection, prevent ischemic injury to tis-
sue , and change other patho-
physiologic events during or around 
transplantation. The most specific of 
these inquiries has been with im-
munosuppression. 
Immunosuppression be-
fore SANDIMMUNE® 
(cyclosporine) * 
By 1960, the possibility of weaken-
ing the recipient immune system in 
order to mitigate rejection had been 
established in animals with cortico-
steroids28 , total body irradiation29, 30, 
and the cytotoxic drug 6-mercap-
topurine31-34 or its imidazole deriva-
tive , azathioprine35 . Sporadic at-
tempts to use these techniques for 
renal homotransplantation in humans 
were so unsuccessfuP, 22, 36, 37, 38 that it 
was widely thought that the im-
munosuppression requisite to prevent 
rejection would inevitably lead to im-
munologic invalidism and lethal infec-
tions. 
*The editor has replaced the author's refer-
ences to cyclosporine by SANDIMMUNE, 
the registered trademark for the cyclo-
sporine product (outside USA, Canada and 
Holland SAN DIMMUN). 
Double-drug therapy with 
azathioprine and steroids 
Renal transplantation became prac-
tical in 1962 and 1963 with the mar-
riage of corticosteroid therapy (pred-
nisone or prednisolone) to baseline 
therapy with azathioprine4, 39. This 
synergistic drug combination, the 
value of which was immediately con-
firmed4o , permitted fundamental ob-
servations to be made, including the 
fact that rejection was a reversible pro-
cess (Figure 2). With the passage of 
time after renal transplantation , a 
change in the relation between the 
graft and the host often occurred , per-
mitting eventual reduction of drug 
doses (Figure 2). Patients who did not 
require chronic high-dose cortico-
steroid therapy to retain their grafts 
have been able to return to useful so-
cial and vocational activities for as 
long as 25 years. The double-drug 
therapy with azathioprine and pred-
nisone remained the gold standard of 
transplantation for many years. 
However, consistently good results 
could be obtained only with transplan-
tation from blood relatives, and even 
then only with good tissue matching 
(see later). This unsatisfactory situa-
tion was a great stimulus to the search 
for better immunosuppressive regi-
mens. 
Triple-drug therapy 
Consequently, modifications of or 
additions to the original double-drug 
treatment were made as summarized 
elsewhere41 during the next 16 years. 
Most of the modifications were de-
signed to blunt the attack of the lym-
phocytes, which had been recognized 
as the mediators of rejection. The 
most significant addition was antilym-
phocyte globulin (ALG) which was 
used as an adjunct to azathioprine and 
prednisone42 . The ALG consisted of 
polyclonal antibodie~ raised in horses, 
rabbits, goats, or other animals by 
immunizing them to human lympho-
cytes ll . When thymic lymphocytes 
were used for immunization , the prod-
uct was called anti thymocyte globulin 
(ATG). The active gamma globulin 
was extracted, purified, and made 
ready for intramuscular or intravenous 
use. Usually, the ALG was adminis-
tered during the first few weeks or 
months after transplantation. 
In spite of its great potential value, 
polyclonal ALG was not universally 
employed as a part of the anti-rejec-
tion armamentarium because of se-
verely limiting features including its 
inability to be standardized. This latter 
problem as well as other deficiencies 
were eliminated with the hybridoma 
technology introduced by Kohler and 
Milstein43 . With hybridoma cells in-
jected into the peritoneum of mice, a 
homogeneous (monoclonal) antihu-
man-lymphocyte antibody could be 
produced. Therapy with monoclonal 
antibodies was introduced into clinical 
medicine by Cosimi et al44 , using the 
so-called OKT3 antibodies which 
selectively deplete mature T-Iympho-
cytes. Their prime objective was to re-
verse kidney graft rejection that was 
non-responsive or poorly responsive 
to conventional corticosteroid therapy 
and azathioprine. OKTI therapy has 
been proved to be of value clinically, 
and it was released in 1986 for general 
use in the United States by the Food 
and Drug Administration (FDA). 
In spite of what had been achieved 
by 1978 with most of the foregoing 
drugs and drug combinations, whole 
organ transplantation remained an un-
predictable and dangerous undertak-
ing especially if cadaver donors were 
used . The margin between effective 
and toxic immunosuppression was too 
narrow. Although the feasibility of 
transplanting the human liver45, 46, 
heart47,48, lung49 , and pancreas50 was 
established in 1967 and 1968, the re-
sults were too poor with any of these 
organs to justify broad application. 
Consequently, the field of transplanta-
tion had a relative growth arrest 
throughout the 1970s, and there 
seemed to be little hope of major im-
provement. The clinical transplant 
sessions at scientific society meetings 
had become tedious expositions in 
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Fig. 1. Renal homograft. (By permission of JAMA 187: 734,1964.) 
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Fig. 2. Rejection crisis in a patient treated with azathioprine. Deterioration of renal function 
began 19 days after transplantation. All stigmata of rejection are present except for acute 
hypertension and weight gain, which were successfully prevented by medical treatment. 
Acti-C-Actinomycin D; LN-Left nephrectomy at time of transplantation; Imuran is synonym-
ous with azathioprine. Note reversal of rejection with what were considered then to be mas-
sive doses of prednisone. The kidney is still functioning morethan 24 years later. (By permis-
sion of Surg Gynecol Obstet 117: 385, 1963.) 
which claims of results , counterclaims , 
and shuffling of details of management 
filled the programs. The boredom was 
shattered with the arrival of cyclo-
sporine (SANDIMMUNE). 
The SAND IMMUNE 
era 
The immunosuppressive qualities 
of this fungus extract were delineated 
by Borel et al51 of Switzerland, and 
the first clinical trials for solid organ 
transplantation were carried out by 
Caine and his associates in Cam-
bridge, England, beginning in the 
spring of 197852,53. 
Renal transplantation 
In Rome during the first week of 
September 1978, the International 
Transplantation Society held its bien-
nial meeting. The members were 
granted an audience with the newly 
proclaimed Pope John Paul I whose 
short tenure sadly ended little more 
than a month later. Encouragement of 
the Catholic church for the transplan-
tation community was forthcoming 
from Pope John Paul along with a re-
minder of the attendant social and 
moral responsibilities. The timing of 
the support and advice could not have 
been more appropriate since the first 
clinical trials with SANDIMMUNE for 
renal transplantation were reported 
from Cambridge during that week, 
along with an impressive array of data 
from several research laboratories. 
The magic of a possible new era was in 
the air . The stages of drug develop-
ment by the Sandoz Pharmaceuticals 
Continued on page 6 
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Division had been a model of scientific 
accuracy and completeness. The 
chemical structure and physical qual-
ities of the drug were completed long 
before Borel et al published studies of 
its immunosuppressive potency, and 
Borel had established dose/effect re-
lationships in several autoimmune 
models as well as after skin grafting in 
rodents51 . 
Fulfillment of the dreams of that 
Italian autumn was not automatic. 
There was a high mortality in the 
1978-79 trials at Cambridge, using 
SANDIMMUNE with other drugs and 
Caine et al recommended that SAND-
IMMUNE be used alone for future 
trials53 . The most encouraging nota-
tion was that a number of the reci-
pients had achieved chronic function 
of transplanted kidneys , livers, or pan-
creases without steroids. However, 
nephrotoxicity was observed univer-
sally, and 3 of the first 34 Cambridge 
recipients developed lymphomas. The 
complications of SANDIMMUNE used 
with other agents were even more se-
vere in further English trials by Sweny 
et a!54 who recommended abandon-
ment of the new drug. 
United States trials of renal trans-
plantation with SANDIMMUNE were 
begun in late 1979 at the Peter Bent 
Brigham Hospital in Boston and at the 
University of Colorado, Denver. Dis-
appointing results, no better than with 
azathioprine and prednisone were re-
ported from the Peter Bent Brigham 
Hospital using SANDIMMUNE as the 
sole drug for the first 2 postoperative 
months55 . The case accrual in Boston 
was slow, and only 16 patients had 
been treated with SANDIMMUNE by 
September 1981, almost 2 years later. 
The other and far more encouraging 
American trial was begun at the Uni-
versity of Colorado and continued at 
the University of Pittsburgh, system at -
ically combining SANDIMMUNE with 
steroids in cadaver kidney recipients56 . 
The ability to control rejection of 
cadaver organs with this drug combi-
nation was greatly improved com-
pared to any therapy in the pastS7 • Of 
equal importance, the maintenance 
steroid doses generally were low 
enough to allow survival without 
cosmetic deformity and other unac-
ceptable morbidity. By late May 1980, 
Table I. Slide presented at ASTS in late May 
1980, discussing the predicted impact of 
cyclosporine which we had been using with 
steroids in Denver since late 1979. 
Strategy of transplantation 
1. Use of living donors will be 
obsolete. 
2. Role oftissue matching will be 
reduced. 
3. Importance of preformed anti-
body analysis will be increased. 
4. Avoidance of sensitization will be 
important. 
5. Diabetics will be easier to treat. 
6. Candidacy criteria will be 
liberalized. 
7. Dialysis/transplantation interface 
will be drastically altered. 
8. Organ supply will become critical. 
we had treated more than 40 renal re-
cipients, and with this experience, I 
prepared a slide for a forum discussion 
at the American Society of Transplant 
Surgeons about where transplantation 
was headed. That slide is reproduced 
verbatim in Table 1. All of the predic-
tions have come true, at least in part. 
The International Transplantation 
Society next met in Boston on 2 to 5 
July 1980, during the American na-
tional holiday celebrating independ-
ence. The advocates of SAND-
IMMUNE slightly outnumbered the 
detractors, but by now two more 
American trials of SANDIMMUNE 
and steroid therapy for renal trans-
plantation had just begun or were 
planned in Minneapolis58 and Hous-
ton59 exploiting the policy of polyphar-
maceutical therapy advanced in the 
Colorado-Pittsburgh trials. With this 
approach, employing drug combina-
tions with additive or synergistic im-
munosuppression, the doses of indi-
vidual agents usually could be kept in 
the non-toxic range. SAND IMMUNE 
and steroids also have been combined 
in later years with azathioprine, and 
polyclonal or monoclonal ALG 
(OKT3). 
The swift dissemination of all of the 
information, good or bad, about 
SAND IMMUNE was done with great 
responsibility on an almost weekly 
basis from Basel and from the 
American Sandoz headquarters in 
East Hanover, New Jersey . Further 
information was exchanged at inter-
national meetings held in September 
1981 in Cambridge60 and in May 1983 
in Houston59. By the first of these 
occasions, extensive data had been 
compiled about transplantation of 
extrarenal organs, and by the second, 
SANDIMMUNE was almost ready to 
be released by the Food and Drug Ad-
ministration (FDA) for general use in 
the United States. When this release 
came in November 1983, there was a · 
generally high degree of understand-
ing about how the drug should be 
used, its side effects, and the expecta-
tions of graft and patient survival. 
One strong recommendation, if not 
absolute condition, of the FDA was 
that SANDIMMUNE administration 
should be carefully guided by monitor-
ing blood levels of the drug. This 
necessitated the introduction in clini-
cal pathology laboratories worldwide 
of new and sophisticated radioim-
munoassay (RIA) or high perfor-
mance liquid chromatography 
(HPLC) techniques developed in 
Basel by the Sandoz scientists. 
By the time SANDIMMUNE was re-
leased, there was a better understand-
ing of the so-called lymphomas which 
had been seen by Caine et ai53, Sweny 
et ai54, and US56, 57. Similar lympho-
proliferative tumors, earlier called re-
ticulum cell sarcomas , had been seen 
frequently under azathioprine-steroid 
therapy with or without ALG61. It was 
realized in the patients treated with 
SANDIMMUNE that these lesions 
probably were caused by Epstein-Barr 
virus infections54, 56, 62, 63. The conven-
tional wisdom until 1983 was that once 
the resulting B cell lymphomas be-
came monoclonal they had achieved 
malignant autonomy and were beyond 
cure62,63 . 
Curiously little thought had been 
given to the obvious expedient of stop-
ping or lightening immunosuppressive 
therapy. When this was done, most of 
the lesions melted away quickly with-
out regard for clonality64. The implica-
tions of these events for an improved 
understanding of host-tumor relation-
ships is considerable, but at a practical 
level , the observations have removed 
the specter of a high SANDIMMUNE 
mortality caused by de novo lymphoid 
malignancies. 
Transplantation of 
vital extrarenal organs 
Because hepatic transplantation is 
the most difficult of all the grafting 
procedures, it is almost incongruous 
that the liver has always been the first 
extrarenal organ to which improve-
ments in management have extended 
from the kidney experience, or from 
which advances have tracked back to 
the kidney. The reason was that those 
working with me or with Roy Caine in 
England on drug development or 
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other aspects of transplantation had a 
lifetime passion to extend what was 
learned with the kidney to the even 
more difficult ultimate objective of 
liver replacement (Figure 3). 
My own first efforts at liver trans-
plantation were begun at Northwest-
ern University in Chicago in the sum-
mer of 195865 . In Boston during the 
same summer, Francis D. Moore inde-
pendently had begun a systematic ex-
ploration of the same possibility66. The 
young English surgeon, Roy Caine, 
came to Harvard in 1960 where in the 
course of his research with im-
munosuppressive drugs35 he was ex-
posed to Moore's work. Caine visited 
Chicago before he returned to Eng-
land. I can remember his courteous 
manner, his determination to see 
everything that was going on, and 
his quick intelligence. Time has not 
dimmed these wonderful qualities. 
Efforts to mitigate liver rejection in 
dogs with irradiation of either the 
donors or recipients failed com-
pletely67. Efforts with azathioprine 
were more successful68, 69 and truly 
long survival was achieved by the mid-
1960s using azathioprine69 , and 
ALG42. The first clinical efforts at liver 
transplantation were made at the Uni-
versity of Colorado in Denver in 
196345 , but the first unequivocal suc-
cesses were not until 196711 ,46. Today, 
the longest survivor in the world is a 
young woman who is married to a 
United States marine stationed in 
Okinawa. She is in her eighteenth 
postoperative year. 
In 1968, Caine began his pioneer 
English program of liver transplanta-
tion70 and before long he established a 
fruitful collaboration with Roger Wil-
liams, the extraordinary hepatologist 
at King's College, London71 . For 
many years, these single American 
and English programs shared the vicis-
situdes and sorrows of defeats more 
common than victories. In all that 
time, I never heard or saw Caine utter 
or write a bitter or complaining word. 
It was fitting that the first 2 liver reci-
pients treated with SANDIMMUNE 
were his patients53. 
The advent of SAND IMMUNE 
changed liver transplantation from an 
exotic experimental procedure to a pa-
tient-service, tripled survival after that 
operation41 , 72, 73 (Figure 4), paved the 
way for more effective transplantation 
of the heart74, 75, 76, and made possible 
the previously unattainable objectives 
of transplanting the heart and lungs77, 
or single lungs78 . The extraordinary 
change that had occurred was already 
reflected in the published collection of 
papers about extrarenal organ trans-
plantation from the Cambridge sym-
posium60 in September 1981. 
The crystal ball 
The intellectual and pragmatic har-
vest made possible by SANDIMMUNE 
goes on. However, the search for im-
proved immunosuppression merely 
has been intensified by what has been 
accomplished. New drugs are being 
evaluated even now of which some are 
even more potent than SAND-
IMMUNE. One example is the experi-
mental drug, FK 506 which was de-
Fig. 3. Completed orthotopic liver transplantation. (By permission of W.B. Saunders Co., 
1969. From Starzl T.E., Experience in Hepatic Transplantation.) 
veloped by the Fujisawa Co. Ltd in 
Japan, first tested by Ochiai in trans-
plant models79 , and made the topic of a 
recent international symposium in 
Sweden80. Whether these new agents 
will have acceptable toxicity, and the 
extent to which they can be used in 
combination with other drugs, must be 
determined. The techniques for rapid 
assessment of immunosuppressive 
drugs including examination of the 
most minute details of their 
mechanisms of action have been part 
of a revolution in the pharmaceutical 
industry which is sure to produce other 
promising drugs. 
Organ procurement 
and preservation 
It had not been perceived that prac-
tical immunosuppression was feasible 
until the synergism of azathioprine 
and steroids was demonstrated with 
startling clarity in 1962 and 1963. At 
that time, a similar void existed in 
organ procurement and preservation. 
Standard techniques did not exist for 
the removal of organs from either liv-
ing or cadaver donors. There was al-
most no understanding by the medical 
and legal professions, much less the 
public at large, of the conditions which 
should govern such activities. Little 
thought or experimentation had been 
devoted to ways with which to treat the 
organ from the time of its removal to 
revascularization in the recipient. 
The principle of core cooling 
The potential benefit of lowering 
the temperature of an excised organ 
was grasped instinctively by early 
workers. In some of the most deliber-
ate applications of this concept, intes-
tinal81 and cardiac grafts25 were pre-
served almost 30 years ago by simple 
immersion in ice cold saline in Dr 
Owen Wangensteen's laboratory at 
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expands by many times the duration of 
organ viability and allows the unhur-
ried application, if desired, of other 
more sophisticated preservation meas-
ures. Different solutions have been 
used. 
Lactated Ringer's solution, the first 
infusate to be used65 , has a low potas-
sium content and is nearly isotonic. 
Chilled special solutions with an elec-
trolyte composition similar to that in 
cells were shown in 1969 by Collins, 
Bravo-Shugarman, and Terasaki83 and 
by others to extend the permissible 
limit of cold renal ischemia beyond 
that achievable with isotonic solu-
tions. The same effect has been shown 
with livers84. Cardiac surgeons have 
cooled the heart with various cardio-
plegic solutions having potassium con-
centrations of 20 to 30 mEq/U5, 76. 
Multiple organ removal procedures 
Until 1981, transplantation of the 
extrarenal organs was a rare event, 
and one which was confined to a hand-
ful of institutions. Although renal 
transplant surgeons were concerned 
that removal of the liver and heart 
could damage kidneys from their 
cadaver renal donors, these anxieties 
were muted by the small number of 
cases involved. However, by late 1981, 
it had become obvious that Liver and 
thoracic organ transplant procedures 
were going to be widespread, and that 
a method of multiple organ procure-
ment would be required by which the 
kidneys, liver, heart, and lungs or vari-
ous combinations of these organs 
could be removed without jeopardiz-
ing any of the individual organs. 
Such a system was developed at the 
University of Pittsburgh hospitals, 
starting with the principle of in situ 
core cooling originally described for 
cadaver kidney procurement by 
Ackerman and Sne1l85 and Merkel, 
Jonasson and Bergan86. At the request 
of the Surgeon General of the United 
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Fig. 4. Life table survival rates for 170 recipients of orthotopic liver transplants treated with 
azathioprine-steroids (March 1963 to February 1980) and 821 recipients treated with SAND-
IMMUNE and steroids (March 1980 to December 1986). Follow-up is complete through 
March 1987. 
the University of Minnesota. How-
ever, even such inefficient attempts at 
surface cooling were not made in any 
of the identical twin renal transplanta-
tions performed through 1962. 
A far more effective way to cool an 
organ is to infuse a cold solution into 
its blood supply (core cooling). This 
simple concept was introduced into 
the laboratory almost 30 years ago to 
make possible liver transplantation in 
the dog65 . Without core cooling, usu-
ally through the portal vein, liver 
transplantation in the dog was not pos-
sible. With core cooling, success be-
came the rule. With such clear evi-
dence, core cooling was promptly 
applied clinically for transplantation 
of the kidney4 and eventually for all 
other organs. 
Even today, the intraoperative infu-
sion of cold fluids at the donor opera-
tion is the essential first step for effec-
tive organ removal and preservation. 
With all organs, the overriding objec-
tive is avoidance of warm ischemia. 
This is achieved by carefully timed in 
situ infusion of cold solutions into 
anatomical regions, the limits of which 
are defined by preliminary dissection 
of the abdominal and/or thoracic aorta 
and cross clamping at those levels82. 
Cooling of an organ graft by the in-
travascular infusion of chilled solu-
tions at the time of circulatory arrest 
States, Dr C. Everett Koop , what had 
become known as the Pittsburgh 
technique was described in detaifU~ K 
Preliminary dissection of the great ves-
sels of the abdomen and chest of the 
donor was carried out so that the or-
gans to be removed could be core 
cooled in situ with cold intraaortic and 
intraportal infusates once the aorta 
had been crossclamped at preplan ned 
levels (Figure 5). 
The technique was adopted as a 
worldwide standard almost overnight. 
Since then, a simplified modification 
of this original procurement proce-
dure has been used which entails virtu-
ally no preliminary dissection of any of 
the organs to be removed87. All organs 
are cooled in situ, and after their cool-
ing, they are rapidly removed by dis-
section in a bloodless field. The inci-
dence of well-functioning kidneys, liv-
ers and hearts has been better than 
with previous methods. 
The collegiality between collaborat-
ing transplantation groups, often from 
different cities, has been greatly im-
proved with the rapid procurement 
operation. Furthermore, the person-
nel at hospitals which are visited by the 
transplantation teams have been al-
most uniformly pleased with the new 
procedure which can usually be car-
ried out in less than 60 minutes from 
beginning to end. 
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Mars, Iowa, USA, in 1926, is Professor of 
Surgery at the University of Pittsburgh 
Medical School , Pittsburgh, Pe nnsylvania , 
USA. 25 years ago he performed the first 
successful cadaveric kidney transplantation . 
Since he has continuously contributed to the 
science and art of transplantation and a pplied 
this knowledge in order to improve patient 
care . His innovative work with transplantation 
of the liver has been even more singularly 
outstanding . After 10 years of experimental 
work he performed the first successful liver 
transplantation in 1967. Since moving from 
University of Colorado Medical School , 
Denver, to Pittsburgh in 1981 he has led the 
development of one of the world 's most suc-
cessful multiple organ transplantation pro-
grams. More than anyone else, Dr. Starzl has 
contributed toward the concepts a nd practice 
of multiorgan transplantation . 
Preservation by 
continuous pedusion 
After their removal, the organs har-
vested with the foregoing techniques 
can be packed in ice chests and kept in 
the special cold solutions already men-
tioned near O°C until their transplanta-
tion within time limits of 6 , 8 , and 48 
hours for the heart , liver, and kidney, 
. respectively. 
Sophisticated techniques for con-
tinuous perfusion of all these organs 
have been developed , but have been 
widely used only for kidney grafts. 
Ackerman and Barnard88 described 
perfusion with cold blood under 
hyperbaric oxygenation . A widely 
used perfusion technique for kidneys 
was described by Belzer , Ashby and 
Dunphy89 using an asanguinous and 
oncotically controlled fluid. The 
method is a good one , but the quality 
of preservation in the first 2 days has 
not been m a rke dly b e tte r tha n w i t h 
the s imple r a nd c hea p er inf u s io n a nd 
'slus h ' m e thods. 
Better continuous perfusion 
t e chniques should permit the exten-
s ion of preservation times of all or-
gans . However , efforts at continuous 
perfusion of hearts and live rs in ex-
perimental laboratories u s ually have 
yielded results inferior to those with 
the simple infusion and refrigeration 
methods . 
Preservation, the orphan 
of transplantation 
It is a curious fact that preservation 
which once seemed the component of 
transplantation most sus ceptible to 
improvement , has been transformed 
so little. This vacuum in development 
was already perceived 17 years ago by 
professional liaison officers at the Na-
tional Institutes of Health who spon-
sored a ' brainstorming' conference at 
which possible approaches to preser-
vation and organ banking were consid-
ered9o• The ideas that surfaced are still 
fresh , but practical improvements 
have not resulted . Aside from the 
presently unattainable objective of 
freezing organs solid , there a ppear to 
be two general approaches that could 
be probed . 
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Fig. 5. Levels of aortic dissection and clamp-
ing for regional core cooling during multiple 
organ procurement. Notice double infusion 
of liver by portal cannula inserted through 
~he inferior mesenteric vein (lMV) as well as 
through the aortic cannula. (By permission 
ofW.B. Saunders Co., 1969. From Starzl T.E., 
Experience in Hepatic Transplantation.) 
One would be to improve the infu-
sion approach by introducing novel in-
gredients into the solution which stays 
in the cold devascularized organ dur-
ing storage, or by using agents to 
minimize the reperfusion injury after 
revascularization in the recipients. 
During the las t decade , various 
m e diators of the inflammatory re-
sponse have been implicated in is-
chemic and postischemic injury. 
Furthermore , some of these mediators 
as well as their inhibitors have been 
synthesized in pharmaceutical re-
search. An important mediator which 
is thought to be central to a wide range 
of pathologic processes is platelet ac-
tivating factor (P AF)91, 92. A P AF-In-
hibitor (PAF-I) has been developed by 
the Sandoz Pharmaceuticals Division 
93, 94 and is being tested for its ability to 
reduce ischemic injury amongst other 
effects . Although numerous other 
specific possibilities could be cited , ef-
forts to foresee his tory in deta il would 
be inappropriate in what is a historical 
perspective. 
The second broad possibility could 
be improved continuous perfusion , 
either at normal or cold temperatures . 
With the remarkable sophistication 
that has characterized research in arti-
ficial organ development , it is amazing 
that continuous perfusion techniques 
today offer so little more for organ 
preservation than they did two de-
cades ago . 
Tissue typing 
Twenty-five years ago when the 
modern era of transplantation was in 
its infancy , it was predicted that tiss ue 
matching would have to be perfected if 
grafting procedures were to succeed. 
In 1964, the firs t efforts were made by 
our Colorado transplant group , work-
ing with Paul I. Terasaki of the Uni-
vers ity of California, Los Angeles 
(UCLA) to prospectively s ele ct ideal 
related or non-related donors for 
specific renal recipients , based on rela-
tively primitive antigen matching95 , 96. 
The res ults w e re disa ppointing . Since 
t h en, t h e validity of tissue matching, 
its gen e tic b asis, a nd a b ove a ll its com-
plexity h a v e b e come increasingly rec-
ognized . The value of tissue m a tching 
for transplantation between f a mily 
m e mbers has been establishe d beyond 
a ny doubt . 
However, the very complexity of 
the human histocompatibility s ystem 
has militated against easy matching 
between non-re late d people. Thus, at 
a pra ctica l level , close matching for 
transplantation of the cadave r kidne y 
has become less and less of a consider-
ation , especially since the availability 
of better immunosuppressive regi-
m e ns made possible by SAND-
IMMUNE . With transplantation of the 
live r , heart and other extrare nal or-
gans, tissue matching has not even 
been taken into consideration because 
the events leading to and connected 
with transplantation occur so quickly 
and often with s uch urgent recipient 
needs that a labored search for a well-
matched organ is not possible . The 
somewhat surprising conclusion has 
been that good results can be obtained 
even with completely mismatched 
cadaver organs . This fact has reduced 
progressively the emphasis on antigen 
matching . 
However , none of the immunosup-
' pressive meas ures available today can 
prevent the immediate destruction of 
kidneys by preformed humoral an-
tibodies in what has been called 
' hyperacute rejection ' . In .1965 , 
Terasaki , Marchioro , and 195 de-
scribed the first example of this 
phenomenon. Kissmeyer-Nielsen et 
al97 of Denmark, Williams et a198, and 
numerous other observers have added 
to an understanding of hyperacute re-
jection . Kidney transplants are the 
most subject to hyperacute rejection, 
but the heart and liver in that order of 
susceptibility also can be similarly de-
s troyed. The proce ss of destruction is 
c a used by thrombotic occlusion of the 
graft microvasculature and con-
s equent devascularization99, 100. Hy-
peracute rejection can be avoided usu-
ally but not invariably by the so-called 
crossmatch test which detects an-
tidonor antibodies in the recipient 
serum in advance of operation. The 
crossmatch has proved to be the single 
most important contribution of tissue 
typers to the practice of transplanta-
tion during the last quarter century101 . 
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It is possible that the effector cas-
cade set into motion by humoral an-
tibodies can be aborted by phar-
macologic intervention. One of the 
most interesting and promising pos-
sibilities was recently reported by 
Makowka et a1102 who used the PAF-I 
m e ntioned earlier in connection with 
organ preservation to delay the 
hyperacute rejection of pig kidneys 
which are normally destroyed by pre-
formed heterospecific antibodies 
within a few minutes after transplanta-
tion to dogs. The same drug can pre-
vent the hyperacute rejection of 
h e terotopic heart grafts transplanted 
to rats presensitized with heart donor 
strain skin grafts l03, and if potent con-
ventional immunosuppression was 
added , long survival followed lO4 . 
The new options 
versus old values 
Developments in transplantation 
and artificial organ technology have 
changed forever the philosophy by 
which organ-defined specialties such 
a s nephrology, hepatology, and car-
diology are practiced . Until recently , 
what could be offered victims of vital 
organ failure was a rear guard ap-
proach designed with diet, medicines, 
or surgical procedures to extract the 
last moment of life-supporting func-
tion from the failing organ. Now, and 
for the first time in human history , the 
breathtaking possibility has emerged 
when all else fails of starting over with 
an organ graft, or (in the not too dis-
tant future) with a manufactured 
organ. Much of the groundwork for 
this revolution was laid in the phar-
maceutical industry. The con-
sequences of changing human ecology 
are well known to those who have 
studied the amplifying effects of an-
tibiotics on the population explosion 
that is said to threaten the earth or at 
least the quality of life of its inhabit-
ants . It remains now to be seen how 
society will manage transplantation, 
the mos t recent product of its cre ativ-
ity and s p o n s o rsh i p . 
Reprint requests should be sent to: Thomas 
E. Starzl, M.D., Ph.D., Department of 
Surgery, 3601 Fifth Avenue, Falk Clinic, 
Pittsburgh, Pennsylvania 15213. 
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